Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intelligent Bio Solutions (INBS) Cash & Equivalents (2020 - 2025)

Intelligent Bio Solutions has reported Cash & Equivalents over the past 4 years, most recently at $1.1 million for Q4 2023.

  • For Q4 2023, Cash & Equivalents fell 61.57% year-over-year to $1.1 million; the TTM value through Dec 2023 reached $1.1 million, down 61.57%, while the annual FY2022 figure was $8.2 million, 34.48% down from the prior year.
  • Cash & Equivalents for Q4 2023 was $1.1 million at Intelligent Bio Solutions, up from $186401.0 in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $19.9 million in Q4 2020 and troughed at $186401.0 in Q3 2023.
  • A 4-year average of $7.9 million and a median of $8.2 million in 2022 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: surged 2842.78% in 2021 and later crashed 96.75% in 2023.
  • Year by year, Cash & Equivalents stood at $19.9 million in 2020, then tumbled by 43.7% to $11.2 million in 2021, then crashed by 73.98% to $2.9 million in 2022, then tumbled by 61.57% to $1.1 million in 2023.
  • Business Quant data shows Cash & Equivalents for INBS at $1.1 million in Q4 2023, $186401.0 in Q3 2023, and $2.3 million in Q1 2023.